Oh I think most stakeholders are keeping a wary eye on this as this year+ stroll down EM lane only added consternation and risk while not leveraging assets.
This forum has pretty much talked through scenarios and speculation and it is just up to the company to take this to the next level and not fumble away such a premier opportunity with multiple candidates.
Meme stocks and speculative stocks are heating up. It is nothing to see some pharmas get bid up over 100 million valuation and with much much less in assets, development potential. I think this easily could be trading around a nickel or more by the time it exits the EM and is accessible by all retail. From there, this could run wild as they appear to have so many irons in the fire with 3 platforms and with the gabakine having a superior best in class preclincal profile, no telling how much money interest is standing with the elephants in the room..
As bigt suggested, it might be a very exciting upcoming months and given all this time, I believe there might be weeks and months of activities and updates to transform this company into a legitimate mid major pharma with multiple clinical trials underway and positioning for multiple additional trials. Investors are anxious to see this all get going. In my opinion and good luck to all...
Market Data 
Markets 
AI
